Background
Phase III, double-blind, placebo-controlled RCT. 666 postmenopausal women with HR+ HER2- advanced breast cancer with no prior systemic therapy for advanced disease. Letrozole backbone. Designed as registration trial for palbociclib in first-line mBC.
Interventions and follow up
Arm A: Palbociclib 125mg days 1–21 of 28-day cycle + letrozole 2.5mg daily
Arm B: Placebo + letrozole 2.5mg daily
Primary endpoint: Progression-free survival (PFS)
mFollow up: 90.0 months (final OS analysis)
Arm B: Placebo + letrozole 2.5mg daily
Primary endpoint: Progression-free survival (PFS)
mFollow up: 90.0 months (final OS analysis)
Results
PFS: 24.8 vs 14.5mo, HR 0.58, 95% CI 0.461–0.723, P<.001
OS (final): 53.9 vs 51.2mo, HR 0.956, 95% CI 0.777–1.177 — not significant
OS (final): 53.9 vs 51.2mo, HR 0.956, 95% CI 0.777–1.177 — not significant
Adverse events
Hematologic (grade ≥3): Neutropenia 66.4% vs 1.4%; febrile neutropenia 1.8%; anemia 5.4%
Dose modification: Dose reduction 36.0%; discontinuation 9.7%
Dose modification: Dose reduction 36.0%; discontinuation 9.7%
Conclusions
Palbociclib + letrozole significantly improved PFS vs letrozole alone in first-line postmenopausal HR+ HER2- mBC but failed to demonstrate an OS benefit at final analysis. OS was numerically similar between arms (53.9 vs 51.2 months), with wide confidence intervals.
Key Limitations
Lack of OS benefit is the major limitation — PFS prolongation (~10 months) did not translate into survival improvement. Post-progression therapies may have diluted OS differences, and a substantial proportion of OS data were censored/missing. Grade ≥3 neutropenia in two-thirds raises tolerability concerns, though febrile neutropenia was rare. No predictive biomarker identified. The OS result contrasts with ribociclib (MONALEESA-2/3/7) and abemaciclib (MONARCH-2/3).
Clinical Context
PALOMA-2 established palbociclib in first-line HR+ HER2- mBC (FDA accelerated approval 2015; confirmed 2017). The negative final OS result contrasts with ribociclib and abemaciclib data, leading some guidelines and clinicians to prefer ribociclib when OS is a primary consideration. Palbociclib remains widely used given its long track record and tolerability. ESMO-MCBS score: 3 (revised after OS results).